A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Advanced Non-Small Cell Lung Carcinoma Clinical Trial

Official title:
A Randomized, Open-Label Study of Combinations of Standard and High Dose REGN2810 (Cemiplimab; Anti-PD-1 Antibody) and Ipilimumab (Anti-CTLA-4 Antibody) in the Second-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer

Status Terminated

Clinical Trial Summary

The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose cemiplimab (SDREGN2810) in the second-line treatment of patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC), in patients whose tumors express programmed cell death ligand 1 (PD-L1) in <50% of tumor cells.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Advanced Non-Small Cell Lung Carcinoma
Carcinoma, Non-Small-Cell Lung

Clinical Trial Details

NCT number	NCT03430063
Study type	Interventional
Source	Regeneron Pharmaceuticals
Contact
Status	Terminated
Phase	Phase 2
Start date	May 29, 2018
Completion date	October 27, 2021

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02171286` - The Oncopanel Pilot (TOP) Study	N/A
	Terminated	`NCT02325349` - PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic Agents	Phase 2